Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomised trial

Lancet

Volumn 351, Issue 9118, 1998, Pages 1755-1762

  Hansson, Lennart ^a   Zanchetti, Alberto ^b   Carruthers, S George ⁱ   Dahlöf, Björn ^c   Elmfeldt, Dag ^a,d   Julius, Stevo ^e   Ménard, Joël ^f   Rahn, Karl Heinz ^g   Wedel, Hans ^h   Westerling, Sten ^d  

^a UPPSALA UNIVERSITY   (Sweden)

^b UNIVERSITY OF MILAN   (Italy)

^c SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^d ASTRAZENECA R AND D   (Sweden)

^e UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^f Centre Opérationnel de Réception et de Régulation des Urgences Sanitaires et Sociales   (France)

^g UNIVERSITY OF MÜNSTER   (Germany)

^h NORDIC SCHOOL OF PUBLIC HEALTH   (Sweden)

ⁱ Nordic School of Public Health ^*

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BAMYCOR; FELODIPINE; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; BLEEDING; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG FATALITY; FEMALE; HEART INFARCTION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK; STROKE;

EID: 0032513878     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(98)04311-6     Document Type: Article

References (33)

1. 1 Hansson L, Zanchetti A, for the HOT Study Group. The Hypertension Optimal Treatment Study (the HOT Study). Blood Press 1993; 2: 62-68.
2. 2 Collins R, Peto R, MacMahon S, et al. Blood pressure, stroke, and coronary heart disease - part 2, short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990; 335: 827-38.
3. 3 Hansson, L. The benefits of lowering elevated blood pressure: a critical review of studies of cardiovascular morbidity and mortality in hypertension. J Hypertens 1996; 14: 537-44.
4. 4 Lindholm L, Ejlertsson G, Scherstén B. High risk of cerebro-cardiovascular morbidity in well treated male hypertensives: a retrospective study of 40-59-year-old hypertensives in a Swedish primary care district. Acta Med Scand 1984; 216: 251-59.
5. 5 Isles CG, Walker L M, Beevers GD, et al. Mortality in patients of the Glasgow Blood Pressure Clinic. J Hypertens 1986; 4: 141-56.
6. 6 Hansson L. How far should blood pressure be lowered? What is the role of the J-curve? Am J Hypertens 1990; 3: 726-29.
7. 7 Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1997; 157: 2413-46.
8. 8 Mancia G, Sega R, Milesi C, Cesana C, Zanchetti A. Blood pressure control in the hypertensive population. Lancet 1997; 349: 454-57.
9. 9 Stewart IM. Relation of reduction in pressure to first myocardial infarction in patients receiving treatment for severe hypertension. Lancet 1979; i: 861-65.
10. 10 Cruickshank J M, Thorp J M, Zacharias F J. Benefits and potential harm of lowering high blood pressure. Lancet 1987; i: 581-84.
11. 11 Alderman, M H, Ooi W L, Madhavan S, Cohen H. Treatment-induced blood pressure reduction and the risk of myocardial infarction. JAMA 1989; 262: 920-24.
12. 12 Samuelsson O, Wilhelmsen L, Andersson OK, Pennert K. Berglund G. Cardiovascular morbidity in relation to change in blood pressure and serum cholesterol levels in treated hypertension: results from the Primary Prevention Trial in Göteborg, Sweden. JAMA 1987; 258: 1768-76.
13. 13 Zanchetti A, Amery A, Berglund G, et al. Clinical round table: how much should blood pressure be lowered? The problem of the J-shaped curve. J Hypertens 1989; 7(suppl 6): 8338-48.
14. 14 Zanchetti A. To what level should blood pressure be brought by antihypertensive treatment? High Blood Press 1992; 1: 197-200.
15. 15 Hennekens CH, Buring JE, Sandercock P, Collins R, Peto R. Aspirin and other antiplatelet agents in the secondary and primary prevention of cardiovascular disease. Circulation 1989; 80: 749-56.
16. 16 The SALT Collaborative Group. Swedish Aspirin Low-dose Trial (SALT) of 75 mg aspirin as secondary prophylaxis after cerebrovascular ischaemic events. Lancet 1991; 338: 1345-49.
17. 17 Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy, 1: prevention of death, myocardial infarction and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994; 308: 81-106.
18. 18 Peto R, Gray R, Collins R, et al. Randomised trial of prophylactic daily aspirin in British male doctors. BMJ 1988; 296: 313-16.
19. 19 Steering Committee of the Physicians' Health Study Research Group. Final report on the aspirin component of the ongoing Physicians' Health Study. N Engl J Med 1989; 321: 129-35.
20. 20 Hansson L, Zanchetti A for the HOT Study Group. The Hypertension Optimal Treatment (HOT) Study-Patient characteristics: randomization, risk profiles, and early blood pressure results. Blood Press 1994; 3: 322-27.
21. 21 Hansson L, Hedner T, Dahlöf B. Prospective Randomized Open Blinded End-point (PROBE) Study: a novel design for intervention trials. Blood Press 1992; 1: 113-19.
22. 22 Pocock SJ, Simon R. Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics 1975; 31: 103-15.
23. 23 O'Brien E, Petrie J, Littler W, et al. The British Hypertension Society protocol for the evaluation of blood pressure measuring devices. J Hypertens 1993; 11 (suppl 2): S43-S62.
24. 24 Lithell H, Berglund L. Validation of an oscillometric blood pressure measuring device: a substudy of the HOT Study. Blood Press (in press).
25. 25 Rose GA, Blackburn H, Gillum RF, Prineas RJ. Classification of the electrocardiogram for population studies. In: Rose GA, Blackburn H, Gillum RF, Prineas RJ, eds. Cardiovascular survey methods. Geneva: WHO, 1982, 123-43.
26. 26 Dahlöf B, Lindholm L, Hansson L, Scherstén B, Ekbom T, Wester P-O. Morbidity and mortality in the Swedish trial in old patients with hypertension (STOP-Hypertension). Lancet 1991; 338: 1281-85.
27. 27 Breslow NE, Day NE. Statistical methods in cancer research, vol 2, The design and analysis of cohort data. Lyon: IARC, 1987.
28. 28 Hansson L, Zanchetti A for the HOT study Group. The Hypertension Optimal Treatment (HOT) Study: 12-month data on blood pressure and tolerability, with special reference to age and gender. Blood Press 1995; 4: 313-19.
29. 29 Hansson L, Zanchetti A for the HOT Study Group. The Hypertension Optimal Treatment (HOT) Study: 24-month data on blood pressure and tolerability. Blood Press 1997; 6: 313-17.
30. 30 Wiklund I, Hailing K, Rydén-Bergsten T, Fletcher A on behalf of the HOT Study Group. Does lowering the blood pressure improve the mood? Quality-of-life results from the Hypertension Optimal Treatment (HOT) Study. Blood Press 1997; 6: 357-64.
31. 31 Medical Research Council Working Party on Mild to Moderate Hypertension. The MRC Mild Hypertension Trial: some subgroup results. In: Strasser T, Gauten D, eds. Mild hypertension: from drug trials to practice. New York: Raven Press, 1987: pp 9-20.
32. 32 The IPPPSH Collaborative Group. Cardiovascular risk and factors in a randomised trial of treatment based on the beta-blocker oxprenolol: The International Prospective Primary Prevention Study in Hypertensives (IPPPSH). J Hypertens 1985; 36: 379-92.
33. 33 Collins R, Peto R. Antihypertensive drugy therapy: effects on stroke and coronary heart disease. In: Swales JD, ed. Textbook of hypertension. Oxford: Blackwell Scientific Publications, 1994: 1156-64.